PRME:ARCA-First Trust Heitman Global Prime Real Estate (USD)

ETF | Biotechnology | NYSE Arca

Last Closing

USD 4.1

Change

0.00 (0.00)%

Market Cap

USD 0.96M

Volume

0.71M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks to provide long-term total return. Under normal market conditions, the fund will seek to achieve its investment objective by investing at least 80% of its net assets (including investment borrowings) in U.S. and non-U.S. exchange-traded real estate securities, which includes real estate investment trusts ("REITs"), real estate operating companies ("REOCs") and common stocks or depositary receipts of companies primarily engaged in the real estate industry (collectively, "RealEstate Securities"). It is non-diversified.

Inception Date: 11/11/2015

Primary Benchmark: FTSE EPRA Nareit Developed TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: NA%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Biotechnology

Symbol Name Mer Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc 0.00 %

-15.02 (-2.91%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc 0.00 %

-2.74 (-0.33%)

USD 92.70B
ALNY Alnylam Pharmaceuticals Inc 0.00 %

+2.39 (+0.86%)

USD 35.78B
ARGX argenx NV ADR 0.00 %

-7.06 (-1.18%)

USD 35.64B
BGNE BeiGene Ltd 0.00 %

-0.43 (-0.21%)

USD 22.85B
MRNA Moderna Inc 0.00 %

-4.08 (-8.71%)

USD 21.00B
UTHR United Therapeutics Corporatio.. 0.00 %

-9.56 (-2.33%)

USD 16.70B
RPRX Royalty Pharma Plc 0.00 %

+0.15 (+0.57%)

USD 16.11B
INCY Incyte Corporation 0.00 %

-1.85 (-2.22%)

USD 14.67B
SMMT Summit Therapeutics PLC 0.00 %

+0.36 (+1.68%)

USD 13.75B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -53.72% 14% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.72% 14% F 13% F
Trailing 12 Months  
Capital Gain -40.10% 14% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.10% 14% F 17% F
Trailing 5 Years  
Capital Gain -79.73% 16% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.73% 16% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain -21.08% 20% F 12% F
Dividend Return -21.08% 20% F 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.25% 92% A 70% C-
Risk Adjusted Return -83.47% 12% F 7% C-
Market Capitalization 0.96M N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector